The pathway's therapeutic vulnerability emerges through SPOP‐GLI3 regulatory axis manipulation, where SPOP depletion‐induced osteopenia and brachydactyly are rescued by GLI3 repressor attenuation [69]. The gene discussed is GLI3; the disease is brachydactyly.